Bariatric Surgery
Conditions
Keywords
Bariatric surgery, Prebiotics, gut microbiota, GLP-1, PYY
Brief summary
In this study, it is aimed to evaluate whether the addition of prebiotics to patients' post-operative diets increases Roux-en-Y Gastric Bypass surgery effects. Half of the participants were randomized prebiotic with conventional yogurt, while the other half were randomized only conventional yogurt as a snack
Detailed description
Following bariatric surgery, positive alterations are observed in gut microbiota, intestinal peptides, and inflammatory cytokines. Previous studies demonstrate that prebiotic use alone in a tolerable dose (which is 10 g/day) among obese, overweight, or diabetic individuals accelerated the weight loss by reducing hunger and food intake. Furthermore, it could also contribute to the improvement of glucose homeostasis by increase postprandial PYY and GLP-1 levels. Prebiotics feeds healthy intestinal bacteria and enhances their positive effects. The present positive effects appear with SCFAs that stimulates PYY and GLP-1 release and produced by fermentation of prebiotics by bacteria. From this point forth, it was hypothesized that post-operative pre-probiotic usage may enhance the effects of Roux-en-Y Gastric Bypass (RYGB). In addition, administration of pre-probiotics following RYGB may be considered as a simple and cheap treatment support, especially for protecting patients with poor medicine compliance against nutritional deficiencies, as well as for diabetic patients whose glucose regulations deteriorate in the long term, and for those who regain weight. With the result that the effects of prebiotic supplementation on metabolic results of RYGB surgery in this prospective, randomized, controlled study with a duration of 24 weeks were tested.
Interventions
Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
The only yogurt consumed as 200 g/d without prebiotic.
Sponsors
Study design
Eligibility
Inclusion criteria
* BMI \>40kg/m2; perform of other types of bariatric surgery except gastric bypass (i.e. sleeve gastrectomy, adjustable gastric band)
Exclusion criteria
I * Administration of antibiotics (other than 1 g ampicillin-sulbactam one hour before surgery), the presence of chronic gastrointestinal, liver or kidney diseases and malignancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma GLP-1 levels changes | 6 months | Change in baseline GLP-1 levels (pM) at 6th month. Measured by plasma samples. |
| Plasma PYY levels changes | 6 months | Change in baseline PYY levels (pg/ml) at 6th month. Measured by plasma samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Appetite regulation | 6 months | Change in baseline appetite at 6th month. Subjective appetite assessed with visual analog scales |
Other
| Measure | Time frame | Description |
|---|---|---|
| excess weight loss changes | 6 months | Change in excess weight loss (%) throughout 6months. |
| weight changes | 6 months | Change in baseline weight (kg) measurements at 6th month. |
| serum insulin changes | 6 months | Change in serum insulin levels (µU/mL) throughout 6months. |
| serum glucose changes | 6 months | Change in serum glucose levels (mg/dl) throughout 6months. |
| fat mass changes | 6 months | Change in baseline fat mass (kg) measurements at 6th month. |
| fat free mass changes | 6 months | Change in baseline fat free mass (kg) measurements at 6th month. |